Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype

Mixture models are applied in population pharmacometrics to characterize underlying population distributions that are not adequately approximated by a single normal or lognormal distribution. In addition to obtaining individualized maximum a posteriori Bayesian post hoc parameter estimates, the subpopulation to which an individual was classified can be determined. However, the accuracy of the classification of subjects to subpopulations is not well studied. We investigated the impact of several factors on the accuracy of classification in mixture models applied to pharmacokinetics using a simulation strategy. The availability of actual subject data allowed us to evaluate mixture model classification in a potentially common application, namely, the classification of clearance into poor metabolizer (PM) or extensive metabolizer (EM) subgroups with the known phenotype status in subjects receiving metoprolol. The factors explored in the simulation study were the magnitude of difference between the clearances in two subpopulations, the between subject variability in clearance, the mixing-fraction, and the population sample size. Populations were simulated at various levels of the above factors and analyzed with a mixture model using NONMEM. The population pharmacokinetics of metoprolol were modeled with the EM/PM phenotype as a known covariate, and without the phenotype covariate using a mixture model. Within the range of scenarios studied, the proportion of subjects classified into the correct subpopulation was high. The simulation–estimation study suggests that a greater separation between two subpopulations, a smaller variability in the parameter distribution, a larger sample size, and a smaller size subpopulation tend to be associated with a greater accuracy of subpopulation classification when a mixture model is applied to pharmacokinetic data. In a population pharmacokinetic analysis of metoprolol, a drug that undergoes polymorphic metabolism, it was possible to correctly identify phenotype status using a mixture model.

[1]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[2]  R. Straka,et al.  Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase. , 1990, Journal of chromatography.

[3]  L. Bertilsson,et al.  Polymorphic Drug Oxidation , 1996 .

[4]  R. Straka,et al.  Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota , 1995, Clinical pharmacology and therapeutics.

[5]  J. Tuomilehto,et al.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. , 1988, JAMA.

[6]  Evaluation of Mixture Modeling with Count Data Using NONMEM , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  B. Burlew,et al.  Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[8]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[10]  K. Hoffmann,et al.  Metabolism of metoprolol-(3-h) in man, the dog and the rat. , 1975, Acta pharmacologica et toxicologica.

[11]  J. Staessen,et al.  Primary Prevention With Metoprolol in Patients With Hypertension , 1988 .

[12]  M. Ingelman-Sundberg,et al.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population , 1992, Clinical pharmacology and therapeutics.

[13]  R. Morris,et al.  Population Pharmacokinetics of Perhexiline From Very Sparse, Routine Monitoring Data , 2001, Therapeutic drug monitoring.

[14]  D. Perrier,et al.  Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients , 2004, European Journal of Clinical Pharmacology.

[15]  C. Meisel,et al.  Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics , 2004, Clinical pharmacology and therapeutics.

[16]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[17]  A. Nafziger,et al.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. , 2000, Pharmacogenetics.

[18]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[19]  I. Zineh,et al.  Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension , 2004, Clinical pharmacology and therapeutics.

[20]  G. Tucker,et al.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. , 1988, The Journal of pharmacology and experimental therapeutics.

[21]  B. Frame,et al.  Population Pharmacokinetics of Ceftizoxime Administered by Continuous Infusion in Clinically Ill Adult Patients , 1998, Antimicrobial Agents and Chemotherapy.